TY - JOUR T1 - Relapse-free cure from multidrug-resistant tuberculosis in Germany JF - European Respiratory Journal JO - Eur Respir J DO - 10.1183/13993003.02122-2017 VL - 51 IS - 2 SP - 1702122 AU - Jan Heyckendorf AU - Frank van Leth AU - Barbara Kalsdorf AU - Ioana D. Olaru AU - Gunar Günther AU - Helmut J.F. Salzer AU - Elena Terhalle AU - Thierry Rolling AU - Georg Glattki AU - Marius Müller AU - Maren Schuhmann AU - Korkut Avsar AU - Christoph Lange Y1 - 2018/02/01 UR - http://erj.ersjournals.com/content/51/2/1702122.abstract N2 - Multidrug-resistant (MDR) tuberculosis (TB), defined by bacillary resistance against rifampicin and isoniazid, has been identified as a global threat to mankind [1]. According to the latest report by the European Centres for Disease Prevention and Control, and World Health Organization (WHO) regional office for Europe, only approximately 50% of MDR-TB patients in Europe reach favourable treatment outcomes [2]. Successful treatment outcomes are achieved for less than 25% of patients with extensively drug-resistant (XDR)-TB (MDR plus resistance against a least one fluoroquinolone and one second-line injectable drug) in the European Union/European Economic Area Countries [2].Under optimal conditions we observed similar rates of relapse-free cure in patients with M/XDR-TB and non-M/XDR-TB http://ow.ly/SRvd30hPu73We thank Cordula Ehlers, Jessica Hofmeister, Franziska Daduna, Nelleke Smitsmann, and Dagmar Schaub for the study management and data entry. ER -